Growth hormone treatment of short children born small for gestational age

Area of Science:

• Pediatric Endocrinology
• Growth Hormone Therapy
• Metabolic Disorders

Background:

• Children born small-for-gestational-age (SGA) are at higher risk for endocrine issues, including growth hormone (GH) deficiency and insulin-like growth factor 1 (IGF-1) resistance.
• SGA children exhibit a diminished growth response to standard GH therapy compared to non-SGA children.

Purpose of the Study:

• To investigate the factors influencing growth response in short SGA children undergoing GH therapy.
• To determine if IGF-1 resistance or GH deficiency is the primary driver of short stature in SGA children.
• To assess the efficacy of higher GH doses in overcoming IGF-1 resistance and achieving normal stature in SGA children.

Main Methods:

• Analysis of growth response in GH-deficient children, comparing those born SGA with non-SGA counterparts.
• Evaluation of the correlation between GH secretory status and growth response to GH therapy in SGA children.
• Comparison of growth outcomes in SGA children treated with standard versus higher doses of GH.

Main Results:

• The growth response of short SGA children to GH therapy is not significantly dependent on endogenous GH secretion, suggesting IGF-1 resistance is predominant.
• Higher doses of GH effectively overcome IGF-1 resistance in SGA children, leading to growth responses comparable to GH-deficient non-SGA children.
• Normal stature can be achieved in SGA children throughout childhood with appropriately adjusted GH therapy.

Conclusions:

• IGF-1 resistance, rather than GH deficiency, is the primary factor limiting growth in most short SGA children.
• Optimizing GH dosage can effectively address IGF-1 resistance and improve growth outcomes in SGA children.
• Future GH therapy for children will likely integrate principles of early-life endocrine programming and personalized dosing strategies.